Inhibition of matrix metalloproteinase-9 for the treatment of dry eye syndrome; a review study

被引：31

作者：

Shoari, Alireza ^{[1
]}

Kanavi, Mozhgan Rezaei ^{[2
]}

Rasaee, Mohammad Javad ^{[1
]}

机构：

[1] Tarbiat Modares Univ, Fac Med Sci, Dept Med Biotechnol, Tehran, Iran

[2] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Res Inst Ophthalmol & Vis Sci, Tehran, Iran

来源：

EXPERIMENTAL EYE RESEARCH | 2021年 / 205卷

关键词：

Matrix metalloproteinase; Dry eye syndrome; Tear production; Corneal barrier; MMP-9; OCULAR SURFACE INFLAMMATION; CONJUNCTIVAL EPITHELIAL APOPTOSIS; MATRIX METALLOPROTEINASES 2; OF-CARE TEST; TOPICAL CYCLOSPORINE; BARRIER DISRUPTION; GLAND-DYSFUNCTION; HEMOPEXIN DOMAIN; DISEASE; MMP-9;

D O I：

10.1016/j.exer.2021.108523

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Dry eye syndrome (DES) and tear dysfunction are multifactorial conditions affecting meibomian glands, lacrimal glands, and ocular surface. This ocular disorder can cause eye irritation, irregular cornea, corneal barrier disruption, and blurred vision. Uncontrolled increase in matrix metalloproteinase-9 (MMP-9) level and activity has been detected in the tears and ocular surface in the patients with DES, which has been proved to be related to disruption of tight junctions in apical corneal epithelium associated with severe signs of DES. These uncontrolled activities of MMP-9 lead to desquamation of ocular surface epithelia. Therefore, this review study was conducted to summarize the evidence regarding MMP-9 contribution in DES, and inhibition of MMP-9, as a therapeutic target for treatment of DES. For this purpose, herein, the related studies designed novel pharmaceutical compounds for direct and indirect inhibition of MMP-9 as treatment approaches for DES were reviewed. These compounds were designed to improve corneal barrier function, reduce inflammation on ocular surface, and restore tear production.

引用

页数：9

共 124 条

[1] Ocular Surface Membrane-Associated Mucins [J].